Anti-CCL2 (Carlumab) -SMCC-DM1

Anti-CCL2 (Carlumab) -SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the linker SMCC (HY-42360) and the cytotoxic microtubule inhibitor DM1 (HY-19792) . The ADC toxic molecule and linker part are SMCC-DM1 (HY-101070) . Anti-CCL2 (Carlumab) -SMCC-DM1 can be used in the research of cancer, especially prostate cancer[1][2].

Product Specifications

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; CCR; Microtubule/Tubulin

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton; GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[Anti-CCL2(Carlumab)-SMCC-DM1]

References & Citations

[1]Fetterly GJ, et al. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol. 2013 Oct;53 (10) :1020-7.|[2]Shao S, et al. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG. Bioorg Med Chem Lett. 2018 May 1;28 (8) :1363-1370.